Karime Berenice Carrillo-Herrera

Karime Berenice Carrillo-Herrera

Auto-generated profile, based on publicly available information

Karime Berenice Carrillo-Herrera

Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2026 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
DRDaniel Ramírez-García
Daniel Ramírez-García
JDJuan Pablo Díaz-Sánchez
Juan Pablo Díaz-Sánchez
KCKarime Berenice Carrillo-Herrera
Karime Berenice Carrillo-Herrera
LCLeslie Alitzel Cabrera-Quintana
Leslie Alitzel Cabrera-Quintana
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
Cardiovascular disease (CVD) is the leading cause of mortality in Latin America, yet most CVD risk equations were developed in high-income countries with limited validations in these settings. Here, we externally validated CVD risk prediction models for fatal CVD, and recalibrated the Globorisk-fatal model in Mexican population. We analyzed 112,262 adults ≥40 years, 67% (75,320) female and 33% (36,942) males, mean age 54.6 ± 10.7 years without prior CVD from the Mexico City Prospective Study. The primary outcome was 10-year fatal CVD, including myocardial infarction (MI) and stroke. CVD risk was estimated using the laboratory- and office-based Framingham, Globorisk, Globorisk-LAC, WHO, and SCORE2 equations. Discrimination was assessed with Harrell's c-statistic and AUROCs, calibration with mean estimates, slopes, and calibration curves, and overall performance with Brier scores. Sex-specific recalibration of the Globorisk-fatal model was performed using observed risks of fatal CVD. During 10 years of follow-up, 2429 fatal CVD events were recorded (1667 MI, 762 stroke). All models showed good discrimination, with c-statistics ranging from 0.761 to 0.805 in males and 0.797–0.831 in females. The Globorisk-fatal model had the highest c-statistic in females (0.831, 95% CI 0.821–0.841), and the laboratory-based WHO-MI model in males (0.805, 95% CI 0.783–0.827). Despite this, all equations consistently overestimated CVD risk, particularly in females. Calibration analyses revealed systematic overprediction at higher risk levels. Recalibration of the Globorisk-fatal model improved agreement between predicted and observed risks. CVD risk models showed good discrimination but consistently overestimated risk in this Mexican cohort. The recalibrated Globorisk-fatal model improves risk estimation of fatal CVD in Mexican adults. This research was supported by Instituto Nacional de Geriatría in Mexico.

22 April 2026 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
JDJuan Pablo Díaz-Sánchez
Juan Pablo Díaz-Sánchez
DRDaniel Ramírez-García
Daniel Ramírez-García
KCKarime Berenice Carrillo-Herrera
Karime Berenice Carrillo-Herrera
LCLeslie Alitzel Cabrera-Quintana
Leslie Alitzel Cabrera-Quintana
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
Cardiovascular disease (CVD) is a leading cause of diabetes-related mortality in Mexico. Although diabetes subgroups capture underlying disease heterogeneity, their association and utility for risk prediction for fatal CVD in Mexican adults remain unclear. Here, we aimed to assess the risk of fatal CVD risk and their complementary role for fatal CVD risk prediction across diabetes subgroups in Mexican adults. We included adults with diabetes from the Mexico City Prospective Study (MCPS). Participants were classified into mild obesity-related (MOD), severe insulin-deficient (SIDD), severe insulin-resistant (SIRD), and mild age-related (MARD) diabetes using a self-normalizing neural network algorithm. Fatal CVD was defined as death from ischemic heart disease or stroke (ICD-10 I20–I25, I60–I69). SCORE2-Diabetes was internally recalibrated for fatal CVD outcomes only for use within MCPS, as this does not represent a formal validation of the original composite endpoint. Cause-specific Cox proportional hazards and Fine & Gray competing risk regression models were used to estimate subgroup-specific risk, and sequential models evaluated the incremental predictive value of diabetes subgroups combined with SCORE2-Diabetes and traditional risk factors. We analyzed data from 24,943 adults living with diabetes (mean age 58 ± 12, 67% female, no ethnicity data available). Over a median follow-up of 19.3 years (IQR 12.7–20.6), 2218 fatal CVD events (8.9%) were recorded. SIDD was the most prevalent subgroup (50.0%), followed by SIRD (14.1%), MARD (17.7%), and MOD (18.3%). SIDD and MARD showed the highest adjusted risk of fatal CVD (HR 1.58 [95% CI 1.38–1.81] and 1.35 [1.13–1.60]), whereas MOD and SIRD had lower risk, even when considering competing causes of non-CVD deaths. Recalibrated SCORE2-Diabetes demonstrated adequate discrimination overall (c-statistic 0.748, 95% CI 0.734–0.762) and for most diabetes subgroups but underperformed in MARD, with internal recalibration for fatal CVD outcomes improving risk assessment. The combination of diabetes subgroups and SCORE2-Diabetes modestly improved prediction for fatal CVD outcomes. Diabetes subgroups show heterogeneity in fatal CVD risk in Mexican adults. SIDD and MARD identify high-risk individuals and integration subgroup classification with SCORE2-Diabetes is complementary for fatal CVD risk prediction. This research was supported by a grant provided by the Bernard Lown Scholars in Cardiovascular Health Program grant number BLSCHP-2403.

16 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
JDJuan Pablo Díaz-Sánchez
Juan Pablo Díaz-Sánchez
DGDaniel Ramírez- García
Daniel Ramírez- García
KCKarime Berenice Carrillo-Herrera
Karime Berenice Carrillo-Herrera
LCLeslie Alitzel Cabrera-Quintana
Leslie Alitzel Cabrera-Quintana
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
BACKGROUND: Cardiovascular disease (CVD) is a leading cause of diabetes-related mortality in Mexico. Although diabetes subgroups capture underlying disease heterogeneity, their association and utility for risk prediction for fatal CVD in Mexican adults remain unclear. METHODS: We analyzed 24,943 adults with diabetes from the Mexico City Prospective Study. Participants were classified into mild obesity-related (MOD), severe insulin-deficient (SIDD), severe insulin-resistant (SIRD), and mild age-related (MARD) diabetes using a self-normalizing neural network algorithm. Fatal CVD was defined as death from ischemic heart disease or stroke (ICD-10 I20–I25, I60–I69). SCORE2-Diabetes was recalibrated and validated overall and by diabetes subgroup. Cox proportional hazards models were used to estimate subgroup-specific risk, and sequential models evaluated the incremental predictive value of diabetes subgroups combined with SCORE2-Diabetes and traditional risk factors. RESULTS: Over a median follow-up of 19.3 years (IQR 12.7-20.6), 2,223 fatal CVD events (8.9%) were recorded. SIDD was the most prevalent subgroup (50.6%), followed by SIRD (17.3%), MARD (16.8%), and MOD (15.4%). SIDD and MARD showed the highest adjusted risk of fatal CVD (RR 1.58 [95%CI 1.38–1.81] and 1.35 [1.13–1.60]), whereas MOD and SIRD had lower risk. Recalibrated SCORE2-Diabetes demonstrated adequate discrimination overall (c-statistic 0.759, 95%CI 0.745-0.773) and for most subgroups but underperformed in MARD, with recalibration improving risk assessment. The combination of diabetes subgroups and SCORE2-Diabetes improved prediction for fatal CVD outcomes. CONCLUSIONS: Diabetes subgroups show heterogeneity in fatal CVD risk in Mexican adults. SIDD and MARD identify high-risk individuals and integration subgroup classification with SCORE2-Diabetes enhances risk prediction.

24 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AMAndrea Malagon-Liceaga
Andrea Malagon-Liceaga
MBMartín Roberto Basile-Alvarez
Martín Roberto Basile-Alvarez
CFCarlos A. Fermín-Martínez
Carlos A. Fermín-Martínez
DRDiana Laura Ramírez-Rivera
Diana Laura Ramírez-Rivera
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
Background: Prediabetes is highly prevalent in older adults and is characterized by heterogeneous clinical trajectories, including regression to normoglycemia and progression to diabetes. While prediabetes has been associated with impaired physical function and frailty, the longitudinal impact of both a single diagnosis and dynamic glycemic transitions on functional outcomes remains unclear. We aimed to evaluate associations between baseline prediabetes and glycemic transitions over time with trajectories of functional capacity and frailty in older adults. Methods: We conducted a pooled analysis of harmonized data from five nationally representative longitudinal aging cohorts (MHAS, HRS, CHARLS, ELSA, CRELES) within the Gateway to Global Aging Data, including adults aged ≥50 years with ≥1 HbA1c measurements. Prediabetes was defined per ADA criteria (HbA1c 5.7-6.4%). Functional outcomes included activities of daily living (ADL), instrumental ADL (IADL), and frailty assessed using Fried phenotype, FRAIL scale, and a deficit-accumulation Frailty Index (FI). Mixed-effects Poisson models estimated incidence rate ratios (IRRs) for baseline prediabetes, while generalized estimating equations assessed time-varying glycemic status and transition trajectories. Models were adjusted for age, sex, cohort, and time-varying covariates, with sensitivity analyses including BMI, smoking, and alcohol intake. Findings: Among 18,571 participants (median follow-up 13.6 years), baseline prediabetes was associated with increased progression of functional deficits and frailty compared with normoglycemia, including higher FI values and accelerated FI progression. Prediabetes was associated with higher incidence of ADL, IADL, and multimorbidity deficits from early follow-up, although time-dependent changes in incidence rates were not significant. In time-varying analyses (n=7,840), both prediabetes and diabetes were associated with higher incidence of functional deficits compared with normoglycemia, with diabetes showing the strongest effects across all outcomes. Diabetes was associated with greater FI burden and accelerated progression, whereas prediabetes showed a smaller increase, with attenuation over time. Among individuals with baseline prediabetes, regression to normoglycemia occurred in 20.8% and was associated with increased incidence of ADL and frailty deficits. In contrast, progression to diabetes occurred in 24.3%, and was associated with lower risk of incident ADL and Fried frailty deficits compared to stable prediabetes. Interpretation: Prediabetes is associated with increased risk of functional decline, frailty, and deficit accumulation in older adults, independent of progression to diabetes. Regression to normoglycemia was associated with higher risk of functional deterioration. These findings suggest that prediabetes reflects a state of metabolic vulnerability linked to biological aging rather than solely a precursor to diabetes and highlights a need to reframe its clinical significance in older populations. Funding: This research was supported by Instituto Nacional de Geriatría in Mexico. RESEARCH IN CONTEXT: Evidence before this study: We searched PubMed up to April 1, 2026, using the terms (“prediabetes”) AND (“frailty” OR “functional decline” OR “activities of daily living” OR “mortality”) AND (“older adults” OR “aging” OR “longitudinal” OR “cohort”). Existing evidence from predominantly single-country and cross-sectional studies suggests that prediabetes is associated with increased risk of frailty, disability, and adverse health outcomes in older adults. However, findings have been inconsistent, particularly regarding incident versus prevalent outcomes and the role of competing risks in aging populations. Importantly, few studies have used harmonized multinational longitudinal data, incorporated repeated measures of glycemic status, or evaluated multiple complementary frailty constructs. The impact of dynamic glycemic transitions, including regression to normoglycemia and progression to diabetes, on functional trajectories remains poorly understood. Added value of this study: This study leverages harmonized longitudinal data from five nationally representative aging cohorts from Mexico, England, China, Costa Rica and the United States to examine both baseline prediabetes and time-varying glycemic status in relation to trajectories of functional decline and frailty. By integrating multiple validated measures of functional capacity and frailty, and applying longitudinal modeling strategies, we provide a comprehensive assessment of the relationship between prediabetes and age-related outcomes. We further characterize glycemic transition trajectories and show that regression to normoglycemia among older adults with prediabetes is associated with increased risk of frailty, while progression to diabetes does not uniformly confer additional risk beyond stable prediabetes. Implications of all the available evidence: Our results support a reconceptualization of prediabetes in older adults as a marker of systemic vulnerability rather than solely a precursor to diabetes. Glycemic status in later life appears to also reflect underlying physiological reserve, with dynamic changes potentially signaling deterioration rather than improvement. Our findings suggest a need to incorporate glycemic markers into geriatric risk stratification and to interpret their changes in the context of aging biology. Future research should focus on elucidating the mechanisms linking dysglycemia with frailty and functional decline, including the roles of sarcopenia, inflammation, and multimorbidity, and on evaluating interventions tailored to older populations across diverse global contexts.